C. Martin Harris
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Colgate-Palmolive dividend focus ahead of Q3 earnings call. Recent coverage lists Colgate‑Palmolive as a dividend champion and a contender for income‑focused investors. The company will host its 2026 third‑quarter earnings webcast on October 30, where results and guidance are expected. Investors noting the upcoming November 13 dividend should be aware of the October 20 record date to qualify for the payment. The stock continues to trade with a dividend yield of about 2.5%.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Claritev Selected by GDIT for WTC Health Program Support. Claritev has been selected by General Dynamics Information Technology (GDIT) to support the World Trade Center Health Program. The financial terms of this agreement were not disclosed. This development adds a notable government-related contract to the company's portfolio, which is relevant context given the stock is currently trading near its 52-week low.
Transaction History
| TMO | ▲ Buy | Grant | 499 | $0 | 5/20/2026 | View on chart |
| CL | ▲ Buy | Grant | 1,556 | $0 | 5/11/2026 | View on chart |
| CTEV | ▲ Buy | Grant | 8,977 | $0 | 4/29/2026 | View on chart |
| TMO | ▲ Buy | Grant | 565 | $0 | 5/21/2025 | View on chart |
| CL | ▲ Buy | Grant | 1,514 | $0 | 5/12/2025 | View on chart |
| CTEV | ▲ Buy | Grant | 7,356 | $0 | 4/30/2025 | View on chart |
| TMO | ▲ Buy | Grant | 339 | $0 | 5/22/2024 | View on chart |
| CL | ▲ Buy | Grant | 1,905 | $0 | 5/13/2024 | View on chart |
| CTEV | ▲ Buy | Grant | 172,413 | $0 | 4/24/2024 | View on chart |
| CL | ▲ Buy | Option Exercise | 2,760 | $171K | 1/31/2024 | View on chart |
| CL | ▼ Sell | Open Market | 2,760 | $233K | 1/31/2024 | View on chart |
| TMO | ▲ Buy | Grant | 392 | $0 | 5/24/2023 | View on chart |
| CL | ▲ Buy | Grant | 2,220 | $0 | 5/15/2023 | View on chart |
| CTEV | ▲ Buy | Grant | 106,382 | $0 | 4/26/2023 | View on chart |
| CL | ▲ Buy | Option Exercise | 5,703 | $409K | 2/21/2023 | View on chart |
| CL | ▼ Sell | Open Market | 5,703 | $423K | 2/21/2023 | View on chart |
| TMO | ▲ Buy | Grant | 369 | $0 | 5/18/2022 | View on chart |
| CL | ▲ Buy | Grant | 2,317 | $0 | 5/9/2022 | View on chart |
| CTEV | ▲ Buy | Grant | 22,271 | $0 | 4/26/2022 | View on chart |
| CL | ▲ Buy | Option Exercise | 4,491 | $322K | 2/2/2022 | View on chart |
| CL | ▼ Sell | Open Market | 4,491 | $372K | 2/2/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Thermo Fisher Outperforms on Life Sciences Recovery
Thermo Fisher Scientific reported strong results driven by a recovery in the life sciences sector. Growth in academic and government spending is supporting demand for the company's products. Analysts note that increasing omics demand could further influence the stock's outlook.
Thermo Fisher Outperforms on Life Sciences Recovery. Thermo Fisher Scientific reported strong results driven by a recovery in the life sciences sector. Growth in academic and government spending is supporting demand for the company's products. Analysts note that increasing omics demand could further influence the stock's outlook.